CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 152 enrolled
Drug / intervention
IPH2102 at 0.1 mg/kg +2 moredrug
Likely dose
IPH2102 at 0.1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01687387
NCT01687387Phase 2Completed
CompareCT.gov

Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission

Innate Pharma·interventional·Posted Sep 18, 2012·Updated Feb 8, 2019

In Brief

A Phase 2 clinical trial evaluating IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg, and 1 other intervention for Acute Myeloid Leukemia. Completed, enrolled 152 participants across 43 sites.

Detailed Summary

Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2012
Enrollment StartOct 1, 2012
Primary CompletionNov 17, 2016
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 13.8 years ago

Interventions

IPH2102 at 0.1 mg/kgdrug

every 3 months

IPH2102 at 1 mg/kgdrug

every 4 weeks

Placebo (normal saline solution)drug

every 4 weeks